Table 3. Cancer quality of life (QoL) questionnaire for individual domains of the QoL with pre- and post-DTX treatment.
| Group A (n=28a) | Group B (n=52b) | |||||
|---|---|---|---|---|---|---|
| Index | Pre-DTX | Post-DTX | P | Pre-DTX | Post-DTX | P |
| Global health status (2–14)c | 5.69±3.28 | 6.75±3.17 | 0.002 | 7.40±2.48 | 7.810±2.45 | 0.186 |
| Functional scalesd | ||||||
| Physical functioning (5–20) | 9.63±2.94 | 9.13±2.66 | 0.088 | 10.20±3.05 | 9.35±2.62 | 0.053 |
| Role functioning (2–8) | 4.69±1.66 | 4.31±1.30 | 0.083 | 4.15±1.76 | 3.75±1.48 | 0.119 |
| Emotional functioning (4–16) | 10.00±3.22 | 10.75±2.70 | 0.247 | 8.70±3.23 | 9.80±2.93 | 0.053 |
| Social functioning (2–8) | 4.50±1.93 | 4.69±1.74 | 0.662 | 4.70±1.98 | 4.50±1.47 | 0.649 |
| Cognitive functioning (2–8) | 4.50±1.03 | 5.06±1.85 | 0.108 | 3.90±1.89 | 4.50±1.70 | 0.062 |
| Symptom scalese | ||||||
| Fatigue (3–12) | 6.57±1.97 | 5.56±1.26 | 0.034 | 5.90±1.71 | 7.00±1.66 | 0.007 |
| Nausea and vomiting (2–8) | 2.06±0.25 | 2.69±1.25 | 0.076 | 2.25±0.72 | 3.20±1.12 | 0.004 |
| Pain (2–8) | 3.87±1.78 | 3.56±1.41 | 0.552 | 4.20±1.61 | 3.80±1.40 | 0.433 |
| Diarrhoea (1–4) | 1.12±0.34 | 1.25±0.58 | 0.497 | 1.20±0.41 | 1.55±0.76 | 0.110 |
| Dyspnoea (1–4) | 1.13±0.34 | 1.31±0.60 | 0.188 | 1.15±0.49 | 1.25±0.44 | 0.428 |
| Insomnia (1–4) | 2.75±0.68 | 2.69±0.79 | 0.806 | 2.75±0.79 | 2.65±0.75 | 0.716 |
| Appetite loss (1–4) | 2.13±0.81 | 2.31±0.79 | 0.333 | 1.85±0.75 | 2.45±0.60 | 0.007 |
| Financial difficulties (1–4) | 3.44±0.73 | 3.06±0.92 | 0.083 | 3.10±0.64 | 3.25±0.44 | 0.379 |
Abbreviation: DTX: docetaxel.
28=42−14 (14 patients did not complete the intermittent regimen).
52=60−8 (8 patients had missing data).
For global health status, 2 corresponded to the worst general condition and 14 corresponded to the best general condition, as perceived by the patient.
For function scales, 5 (physical functioning), 2 (role, social, cognitive) and 4 (emotional) referred to no impairment in corresponding functioning, and 20, 8 and 16 corresponded to severe impairment of functioning, respectively.
For symptom scales, 3 (fatigue), 2 (nausea/vomiting, pain) and 1 (diarrhoea, dyspnoea, insomnia, appetite loss, financial difficulties) corresponded to an absence of symptoms, and 12, 8 and 4 corresponded to the most intense form of symptoms, respectively.